A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.

International Partnership for Microbicides, Inc.4 sites in 3 countries112 target enrollmentOctober 2005

ConditionsHIV Infections

Drugsdapivirine (TMC120) vaginal gel

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: HIV Infections
Sponsor: International Partnership for Microbicides, Inc.
Enrollment: 112
Locations: 4
Primary Endpoint: Local and systemic safety and tolerability.
Status: Completed
Last Updated: 19 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or matching placebo gel. The volunteers will receive investigational product for a total of 42 days. Volunteers will be monitored on days 7, 28 and 42 for safety, tolerability and compliance.

Registry

clinicaltrials.gov

Start Date

October 2005

End Date

July 2006

Last Updated

19 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

International Partnership for Microbicides, Inc.

Eligibility Criteria

Inclusion Criteria

•HIV-negative
•Willing to participate and sign an informed consent
•Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group.
•Willing to use two forms of contraception during the study.
•Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study.
•Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses.
•Willing to abstain from using any vaginal product (other than the study product or placebo).
•Willing to be sexually abstinent from randomization until completion of Day 7 evaluations.

Exclusion Criteria

•Currently pregnant or breast-feeding.
•Clinically detectable genital abnormality on the vulva, vaginal walls or cervix.
•Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions.
•Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization.
•Symptomatic bacterial vaginosis and unwilling to undergo treatment.
•Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.